<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="1-part\PMC6370234\results\search\tropicalVirus\results.xml">
  <result pre="sciences : Organisms : Viruses : RNA viruses : Flaviviruses:" exact="Zika" post="Virus : Biology and Life Sciences : Microbiology :"/>
  <result pre="Medical Microbiology : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : Medicine and Health Sciences : Pathology and"/>
  <result pre=": Pathogens : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : Biology and Life Sciences : Organisms :"/>
  <result pre="Sciences : Organisms : Viruses : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : Medicine and Health Sciences : Infectious Diseases"/>
  <result pre="sciences : Organisms : Viruses : RNA viruses : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Microbiology :"/>
  <result pre="Medical Microbiology : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Medicine and Health Sciences : Pathology and"/>
  <result pre=": Pathogens : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Organisms :"/>
  <result pre="Sciences : Organisms : Viruses : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Research and Analysis Methods : Research Assessment:"/>
  <result pre="syndrome Does prior dengue virus exposure worsen clinical outcomes of" exact="Zika" post="virus infection? A systematic review, pooled analysis and lessons"/>
  <result pre="learned Does prior dengue virus exposure worsen clinical outcomes of" exact="Zika" post="virus infection? MaselJenniferData curationInvestigationMethodologyProject administrationWriting – original draft1McCrackenMichael K.Data"/>
  <result pre="available under the Creative Commons CC0 public domain dedication.pntd.0007060.pdf Abstract" exact="Zika" post="virus (ZIKV) recently caused a pandemic complicated by Guillain-Barre"/>
  <result pre="a pandemic complicated by Guillain-Barre syndrome (GBS) and birth defects." exact="ZIKV" post="is structurally similar to the dengue viruses (DENV) and"/>
  <result pre="and in vitro studies suggest antibody dependent enhancement occurs in" exact="ZIKV" post="infections preceded by DENV; however, the clinical significance of"/>
  <result pre="to DENV-naïve hosts, is associated with a greater risk of" exact="ZIKV" post="clinical complications or greater ZIKV peak viremia in vivo."/>
  <result pre="with a greater risk of ZIKV clinical complications or greater" exact="ZIKV" post="peak viremia in vivo. We identified 1146 studies in"/>
  <result pre="study indicated no increase in the risk of GBS in" exact="ZIKV" post="infections with prior DENV exposure. Two additional human studies"/>
  <result pre="in the risk of GBS in ZIKV infections with prior" exact="DENV" post="exposure. Two additional human studies showed a small increase"/>
  <result pre="exposure. Two additional human studies showed a small increase in" exact="ZIKV" post="viremia in those with prior DENV exposure; however, this"/>
  <result pre="a small increase in ZIKV viremia in those with prior" exact="DENV" post="exposure; however, this was not statistically significant nor was"/>
  <result pre="only weak evidence of a 0.39 log10 GE/mL rise in" exact="ZIKV" post="viremia in DENV experienced rhesus macaques compared to those"/>
  <result pre="of a 0.39 log10 GE/mL rise in ZIKV viremia in" exact="DENV" post="experienced rhesus macaques compared to those with no DENV"/>
  <result pre="in DENV experienced rhesus macaques compared to those with no" exact="DENV" post="exposure (p = 0.22). Using a customized quality grading"/>
  <result pre="human studies have offered high quality measurement of both acute" exact="ZIKV" post="and antecedent DENV infections. In conclusion, limited human and"/>
  <result pre="offered high quality measurement of both acute ZIKV and antecedent" exact="DENV" post="infections. In conclusion, limited human and NHP studies indicate"/>
  <result pre="NHP studies indicate a small and non-statistically significant increase in" exact="ZIKV" post="viremia in DENV-experienced versus DENV-naïve hosts; however, there is"/>
  <result pre="is no evidence that even a possible small increase in" exact="ZIKV" post="viremia would correlate with a change in ZIKV clinical"/>
  <result pre="increase in ZIKV viremia would correlate with a change in" exact="ZIKV" post="clinical phenotype. More data derived from larger sample sizes"/>
  <result pre="major relevance for clinical prognosis and vaccine design. Author summary" exact="Zika" post="virus (ZIKV) is a mosquito borne virus that recently"/>
  <result pre="high-order animal literature to synthesize the current evidence about whether" exact="ZIKV" post="outcomes are worse in those with previous DENV exposure."/>
  <result pre="about whether ZIKV outcomes are worse in those with previous" exact="DENV" post="exposure. We further undertook a pooled analysis across the"/>
  <result pre="We summarize that, in humans and in non-human primates, prior" exact="DENV" post="exposure may lead to a small increase in ZIKV"/>
  <result pre="prior DENV exposure may lead to a small increase in" exact="ZIKV" post="viral load during infection. However, we do not show"/>
  <result pre="However, we do not show that any possible increase in" exact="ZIKV" post="viral replication is associated with a higher rate of"/>
  <result pre="ZIKV viral replication is associated with a higher rate of" exact="Zika" post="complications or Zika clinical severity. We further graded the"/>
  <result pre="is associated with a higher rate of Zika complications or" exact="Zika" post="clinical severity. We further graded the quality of these"/>
  <result pre="and indicate that substantial improvements in the immunological measurement of" exact="ZIKV" post="and DENV exposure in humans are needed to answer"/>
  <result pre="that substantial improvements in the immunological measurement of ZIKV and" exact="DENV" post="exposure in humans are needed to answer these and"/>
  <result pre="are within the manuscript and its Supporting Information files. Introduction" exact="Zika" post="virus is a flavivirus primarily transmitted by Aedes aegypti"/>
  <result pre="by Guillain-Barre syndrome (GBS), microcephaly and other birth defects [1]." exact="ZIKV" post="was first discovered in Uganda in 1947 and was"/>
  <result pre="asymptomatic infection [4, 5]. In 2015 and 2016 an explosive" exact="ZIKV" post="outbreak spread through South America, Central America, and the"/>
  <result pre="retrospect during the French Polynesia outbreak, it became evident that" exact="ZIKV" post="was associated with GBS and congenital Zika syndrome (CZS)"/>
  <result pre="became evident that ZIKV was associated with GBS and congenital" exact="Zika" post="syndrome (CZS) [5, 7]. Congenital infections were associated with"/>
  <result pre="reports as early as 2011, it was also observed that" exact="ZIKV" post="infection could be transmitted sexually during the neotropical epidemic"/>
  <result pre="be transmitted sexually during the neotropical epidemic [9–12]. Although the" exact="ZIKV" post="pandemic has now waned in the Americas [13], there"/>
  <result pre="regions, some of which have already evidently experienced long term" exact="ZIKV" post="circulation as well as substantial recent outbreaks, in addition"/>
  <result pre="cohorts [14–16]. An especially striking feature of the most recent" exact="ZIKV" post="outbreak is the breadth of phenotypes, ranging from asymptomatic"/>
  <result pre="severe complications such as GBS and CZS [17]. Investigators studying" exact="ZIKV" post="noted that the virus shares its vector and geographic"/>
  <result pre="For example, geographic regions of Northern Brazil that experienced substantial" exact="ZIKV" post="case burdens are also known to have a DENV"/>
  <result pre="substantial ZIKV case burdens are also known to have a" exact="DENV" post="seroprevalence exceeding 90% in adults [19]. Sequential DENV infections"/>
  <result pre="have a DENV seroprevalence exceeding 90% in adults [19]. Sequential" exact="DENV" post="infections with different serotypes are associated with more severe"/>
  <result pre="serotypes are associated with more severe disease than infections in" exact="DENV" post="immune patients. This is believed by many investigators to"/>
  <result pre="thereby facilitating viral entry and leading to increased viremia [20]." exact="ZIKV" post="and DENV have substantial proteomic homology, and the humoral"/>
  <result pre="viral entry and leading to increased viremia [20]. ZIKV and" exact="DENV" post="have substantial proteomic homology, and the humoral immunological interactions"/>
  <result pre="ZIKV, in particular the cross reactivity of antibodies generated by" exact="DENV" post="exposure [21, 22]. Early in the ZIKV Americas epidemic,"/>
  <result pre="antibodies generated by DENV exposure [21, 22]. Early in the" exact="ZIKV" post="Americas epidemic, several in vitro and murine studies suggested"/>
  <result pre="epidemic, several in vitro and murine studies suggested that prior" exact="DENV" post="infection may not only fail to cross-neutralize ZIKV but"/>
  <result pre="that prior DENV infection may not only fail to cross-neutralize" exact="ZIKV" post="but also may lead to ZIKV ADE, greater ZIKV"/>
  <result pre="only fail to cross-neutralize ZIKV but also may lead to" exact="ZIKV" post="ADE, greater ZIKV viremia and, therefore, perhaps increased clinical"/>
  <result pre="cross-neutralize ZIKV but also may lead to ZIKV ADE, greater" exact="ZIKV" post="viremia and, therefore, perhaps increased clinical morbidity upon subsequent"/>
  <result pre="ZIKV viremia and, therefore, perhaps increased clinical morbidity upon subsequent" exact="ZIKV" post="exposure. Priyamvada et al showed that both DENV-exposed sera"/>
  <result pre="monoclonal antibodies from DENV-infected individuals in Thailand enhanced in vitro" exact="ZIKV" post="infection in the U937 cell lines [23]. Dejnirattisai et"/>
  <result pre="the U937 cell lines [23]. Dejnirattisai et al noted that" exact="DENV" post="experienced human sera collected from Thailand potently cross-reacted, poorly"/>
  <result pre="sera collected from Thailand potently cross-reacted, poorly neutralized and induced" exact="ZIKV" post="ADE in ZIKV PF13 or HD78788 inoculated U937 myeloid"/>
  <result pre="Thailand potently cross-reacted, poorly neutralized and induced ZIKV ADE in" exact="ZIKV" post="PF13 or HD78788 inoculated U937 myeloid cell lines [24]."/>
  <result pre="from DENV-3 exposed humans led to the enhanced replication of" exact="ZIKV" post="PE/243 in FcγRII-expressing K562 cell lines [19]. Bardinha et"/>
  <result pre="Bardinha et al also showed in vitro evidence of DENV-induced" exact="ZIKV" post="ADE using Puerto Rican DENV experienced donor sera in"/>
  <result pre="in vitro evidence of DENV-induced ZIKV ADE using Puerto Rican" exact="DENV" post="experienced donor sera in ZIKV infected K562 cell lines,"/>
  <result pre="ZIKV ADE using Puerto Rican DENV experienced donor sera in" exact="ZIKV" post="infected K562 cell lines, and further showed evidence that"/>
  <result pre="human hosts led to increased morbidity and paralysis in PRVABC59" exact="ZIKV" post="infections compared to those that received control plasma. These"/>
  <result pre="contrast to earlier in vitro data which indicated that cross-reactive" exact="DENV" post="antibodies from human natural infections actually neutralized a range"/>
  <result pre="antibodies from human natural infections actually neutralized a range of" exact="ZIKV" post="strains [26]. Since these early studies, which generated alarm"/>
  <result pre="animal evidence and provided a current consensus on whether prior" exact="DENV" post="infection is indeed a risk factor for worsened ZIKV"/>
  <result pre="prior DENV infection is indeed a risk factor for worsened" exact="ZIKV" post="clinical outcomes such as GBS, CZS or whether prior"/>
  <result pre="ZIKV clinical outcomes such as GBS, CZS or whether prior" exact="DENV" post="exposure changes possible laboratory proxies of severity such as"/>
  <result pre="DENV exposure changes possible laboratory proxies of severity such as" exact="ZIKV" post="viremia or inflammatory cytokine profiles. Resolving this question is"/>
  <result pre="question is critical for both clinical prognosis of those with" exact="ZIKV" post="infection as well as DENV vaccine implementation in areas"/>
  <result pre="clinical prognosis of those with ZIKV infection as well as" exact="DENV" post="vaccine implementation in areas endemic to both ZIKV and"/>
  <result pre="well as DENV vaccine implementation in areas endemic to both" exact="ZIKV" post="and DENV [28]. We therefore undertook a systematic review"/>
  <result pre="DENV vaccine implementation in areas endemic to both ZIKV and" exact="DENV" post="[28]. We therefore undertook a systematic review to determine"/>
  <result pre="infection with DENV, as compared to those with no prior" exact="DENV" post="infection, is associated with a greater risk of ZIKV"/>
  <result pre="prior DENV infection, is associated with a greater risk of" exact="ZIKV" post="complications (including neurological and teratogenic outcomes), greater ZIKV peak"/>
  <result pre="risk of ZIKV complications (including neurological and teratogenic outcomes), greater" exact="ZIKV" post="peak viremia, greater area-under-the-curve (AUC) of viremia or other"/>
  <result pre="area-under-the-curve (AUC) of viremia or other putative laboratory proxies of" exact="ZIKV" post="severity. While a meta-analysis of human data was not"/>
  <result pre="of existing studies, in particular the validity of how acute" exact="ZIKV" post="and prior DENV exposure were measured. Collectively, our findings"/>
  <result pre="in particular the validity of how acute ZIKV and prior" exact="DENV" post="exposure were measured. Collectively, our findings offer a timely"/>
  <result pre="a timely update in the current understanding of how clinical" exact="ZIKV" post="outcomes are changed by prior DENV exposure, emphasize caution"/>
  <result pre="understanding of how clinical ZIKV outcomes are changed by prior" exact="DENV" post="exposure, emphasize caution in how in vitro and small"/>
  <result pre="for improved sero-diagnostic methods in areas experiencing syndemics of DENV," exact="ZIKV" post="and other medically important flaviviruses. Methods We followed PRISMA"/>
  <result pre="primate (NHP) studies in which the outcomes of those with" exact="ZIKV" post="infection preceded by DENV exposure, was compared to the"/>
  <result pre="which the outcomes of those with ZIKV infection preceded by" exact="DENV" post="exposure, was compared to the outcomes of those with"/>
  <result pre="DENV exposure, was compared to the outcomes of those with" exact="ZIKV" post="infection without prior DENV infection. ZIKV infection was defined"/>
  <result pre="to the outcomes of those with ZIKV infection without prior" exact="DENV" post="infection. ZIKV infection was defined as molecular detection in"/>
  <result pre="outcomes of those with ZIKV infection without prior DENV infection." exact="ZIKV" post="infection was defined as molecular detection in blood, urine,"/>
  <result pre="biological human specimen, and/or positive serology consistent with acute infection." exact="DENV" post="exposure was defined as a documented prior clinically or"/>
  <result pre="was defined as a documented prior clinically or laboratory diagnosed" exact="DENV" post="infection, known experimental inoculation with DENV (for example, in"/>
  <result pre="clinically or laboratory diagnosed DENV infection, known experimental inoculation with" exact="DENV" post="(for example, in NHPs), or serology consistent with prior"/>
  <result pre="DENV (for example, in NHPs), or serology consistent with prior" exact="DENV" post="exposure. We included studies which measured any of the"/>
  <result pre="in conjunction with non-neutralizing antibodies or other laboratory evidence of" exact="Zika" post="severity, fetal microcephaly, fetal loss or other malformation, CZS,"/>
  <result pre="evaluating the quality of how prior dengue exposure and current" exact="ZIKV" post="infection was determined (S1 Table). No review investigator graded"/>
  <result pre="the study methods presented in a reproducible way? Was prior" exact="DENV" post="exposure measured in a valid way? Was acute ZIKV"/>
  <result pre="prior DENV exposure measured in a valid way? Was acute" exact="ZIKV" post="exposure measured in a valid way? Were clinical outcomes"/>
  <result pre="of patients with ZIKV-associated GBS during the 2013–2014 French Polynesia" exact="ZIKV" post="outbreak, which coincided with a substantial increase in the"/>
  <result pre="in the incidence of GBS and an apparent co-circulation of" exact="DENV" post="serotypes 1 and 3 in French Polynesia [5]. The"/>
  <result pre="= 70) consisted of age-matched patients with RT-PCR confirmed acute" exact="ZIKV" post="infection with no neurological complications. The investigators measured DENV"/>
  <result pre="acute ZIKV infection with no neurological complications. The investigators measured" exact="DENV" post="and ZIKV exposure using several assays, not all of"/>
  <result pre="infection with no neurological complications. The investigators measured DENV and" exact="ZIKV" post="exposure using several assays, not all of which were"/>
  <result pre="specimen from the GBS and CTR2 group underwent testing for" exact="ZIKV" post="using a RT-PCR assay. A single acute specimen from"/>
  <result pre="specimen from the GBS and CTR1 group was tested for" exact="DENV" post="and ZIKV IgM using an indirect immunofluorescence assay. Single"/>
  <result pre="the GBS and CTR1 group was tested for DENV and" exact="ZIKV" post="IgM using an indirect immunofluorescence assay. Single acute specimens"/>
  <result pre="from the GBS, CTR1 and CTR2 groups were tested for" exact="ZIKV" post="and DENV IgG using a recombinant-antigen based microsphere immunoassay."/>
  <result pre="GBS, CTR1 and CTR2 groups were tested for ZIKV and" exact="DENV" post="IgG using a recombinant-antigen based microsphere immunoassay. In addition,"/>
  <result pre="specimens from the GBS and CTR1 groups were tested for" exact="ZIKV" post="and DENV neutralizing antibodies using a microseroneutralization assay. While"/>
  <result pre="the GBS and CTR1 groups were tested for ZIKV and" exact="DENV" post="neutralizing antibodies using a microseroneutralization assay. While serial ZIKV"/>
  <result pre="and DENV neutralizing antibodies using a microseroneutralization assay. While serial" exact="ZIKV" post="and DENV serology was performed in the GBS group,"/>
  <result pre="neutralizing antibodies using a microseroneutralization assay. While serial ZIKV and" exact="DENV" post="serology was performed in the GBS group, logistic regression"/>
  <result pre="the GBS group, logistic regression analysis to determine whether prior" exact="DENV" post="exposure was more likely in ZIKV+/GBS+ cases compared to"/>
  <result pre="single time-point serological measurement. None of the GBS group were" exact="ZIKV" post="RT-PCR positive (0 of the 41 tested from the"/>
  <result pre="IgM and were also anti-DENV IgM negative. By combining these" exact="ZIKV" post="IgM results with the ZIKV IgG results, the authors"/>
  <result pre="IgM negative. By combining these ZIKV IgM results with the" exact="ZIKV" post="IgG results, the authors determined that 97.6% of the"/>
  <result pre="the microneutralization assay, 100% of the GBS group were deemed" exact="ZIKV" post="exposed. Of this GBS+/ZIKV+ group (n = 42), the"/>
  <result pre="group (n = 42), the majority (40/42 or 95.2%) were" exact="DENV" post="IgG+. No statistically significant difference in DENV IgG+ positivity"/>
  <result pre="or 95.2%) were DENV IgG+. No statistically significant difference in" exact="DENV" post="IgG+ positivity was observed in GBS cases compared with"/>
  <result pre="cases compared with control group 1 which had 87/98 (88.8%)" exact="DENV" post="IgG+ individuals (OR = 2.0; 95% CI = 0.4–19.9;"/>
  <result pre="= 0.62). Similarly, no statistically significant difference was observed in" exact="DENV" post="IgG+ GBS cases when compared with the CTR2 group"/>
  <result pre="with the CTR2 group that was comprised of 58/70 (82.9%)" exact="DENV" post="IgG+ individuals (OR = 6.04; 95% CI = 0.81–269.5;"/>
  <result pre="CI = 0.81–269.5; p = 0.10). Terzian et al described" exact="ZIKV" post="viral load and cytokine responses in patients presenting with"/>
  <result pre="viral load and cytokine responses in patients presenting with acute" exact="ZIKV" post="infection in Sao Paulo, Brazil in early 2016 [41]."/>
  <result pre="in early 2016 [41]. They sampled 45 patients with acute" exact="ZIKV" post="infection at a single time point, with acute ZIKV"/>
  <result pre="acute ZIKV infection at a single time point, with acute" exact="ZIKV" post="infection determined by testing for ZIKV, DENV and CHIKV"/>
  <result pre="point, with acute ZIKV infection determined by testing for ZIKV," exact="DENV" post="and CHIKV by RT-PCR. Prior DENV status was ascertained"/>
  <result pre="acute ZIKV infection determined by testing for ZIKV, DENV and" exact="CHIKV" post="by RT-PCR. Prior DENV status was ascertained by a"/>
  <result pre="by testing for ZIKV, DENV and CHIKV by RT-PCR. Prior" exact="DENV" post="status was ascertained by a commercial DENV IgG ELISA"/>
  <result pre="by RT-PCR. Prior DENV status was ascertained by a commercial" exact="DENV" post="IgG ELISA assay. ZIKV viral load was measured by"/>
  <result pre="status was ascertained by a commercial DENV IgG ELISA assay." exact="ZIKV" post="viral load was measured by quantitative PCR. Cytokine profiles"/>
  <result pre="load was measured by quantitative PCR. Cytokine profiles in acute" exact="ZIKV" post="infections were estimated using a multiplex bead analysis assay"/>
  <result pre="IL-13, and IL-17. Of those 45 patients with molecularly confirmed" exact="ZIKV" post="infection, 35 were DENV IgG positive and 10 were"/>
  <result pre="those 45 patients with molecularly confirmed ZIKV infection, 35 were" exact="DENV" post="IgG positive and 10 were DENV IgG negative, indicating"/>
  <result pre="ZIKV infection, 35 were DENV IgG positive and 10 were" exact="DENV" post="IgG negative, indicating the majority had prior DENV exposure."/>
  <result pre="10 were DENV IgG negative, indicating the majority had prior" exact="DENV" post="exposure. Those acute ZIKV infections which were DENV IgG+"/>
  <result pre="negative, indicating the majority had prior DENV exposure. Those acute" exact="ZIKV" post="infections which were DENV IgG+ did have higher median"/>
  <result pre="had prior DENV exposure. Those acute ZIKV infections which were" exact="DENV" post="IgG+ did have higher median viral load than those"/>
  <result pre="did have higher median viral load than those who were" exact="DENV" post="IgG-, but the difference in median VL (log10 PFU/ml)"/>
  <result pre="IgG-, but the difference in median VL (log10 PFU/ml) between" exact="DENV" post="IgG +/- subjects was small (&quot;least significant difference of"/>
  <result pre="adequately powered to detect a greater than 10-fold difference in" exact="ZIKV" post="viremia between the 2 groups. While there was evidence"/>
  <result pre="While there was evidence that IL-1β activation was correlated with" exact="ZIKV" post="viral load, there was no statistically significant difference in"/>
  <result pre="and IL-9 levels in a comparative analysis of acute PCR-confirmed" exact="DENV" post="infections who were DENV IgG- compared to those who"/>
  <result pre="a comparative analysis of acute PCR-confirmed DENV infections who were" exact="DENV" post="IgG- compared to those who were DENV IgG positive"/>
  <result pre="infections who were DENV IgG- compared to those who were" exact="DENV" post="IgG positive (with a statistical significance corresponding to p-values"/>
  <result pre="data. Halai et al studied 131 pregnant women with acute" exact="ZIKV" post="infection, as part of a prospective cohort of 345"/>
  <result pre="medical care in Rio de Janeiro with new onset rash." exact="ZIKV" post="infection was confirmed by RT-PCR on serum and/or urine."/>
  <result pre="was confirmed by RT-PCR on serum and/or urine. A standardized" exact="ZIKV" post="clinical severity score was developed and applied. The score"/>
  <result pre="rash, duration of illness, duration of fever, and multisystem involvement." exact="DENV" post="status was ascertained by IgG ELISA. ZIKV viremia was"/>
  <result pre="and multisystem involvement. DENV status was ascertained by IgG ELISA." exact="ZIKV" post="viremia was measured by PCR cycle threshold (CT) and"/>
  <result pre="pregnancy, and adverse birth outcomes occurred in 46.4% of those" exact="ZIKV" post="infected participants with available birth outcome data. Prior DENV"/>
  <result pre="those ZIKV infected participants with available birth outcome data. Prior" exact="DENV" post="exposure was measured by a single specimen obtained at"/>
  <result pre="by a single specimen obtained at the time of acute" exact="ZIKV" post="infection using a commercial DENV IgG serological assay. Median"/>
  <result pre="at the time of acute ZIKV infection using a commercial" exact="DENV" post="IgG serological assay. Median ZIKV RNA by PCR CT"/>
  <result pre="ZIKV infection using a commercial DENV IgG serological assay. Median" exact="ZIKV" post="RNA by PCR CT was 31 in DENV IgG+"/>
  <result pre="assay. Median ZIKV RNA by PCR CT was 31 in" exact="DENV" post="IgG+ women and 32 for DENV IgG- (that is,"/>
  <result pre="CT was 31 in DENV IgG+ women and 32 for" exact="DENV" post="IgG- (that is, higher viremia in the DENV IgG+"/>
  <result pre="32 for DENV IgG- (that is, higher viremia in the" exact="DENV" post="IgG+ group); however, this difference was not statistically significant"/>
  <result pre="not statistically significant (p = 0.153). In those positive for" exact="DENV" post="IgG, the median clinical severity score was 7 (moderate"/>
  <result pre="from the median clinical severity score of 7.5 in the" exact="DENV" post="IgG negative group (p = 0.166). Additionally, being positive"/>
  <result pre="IgG negative group (p = 0.166). Additionally, being positive for" exact="DENV" post="IgG+ was not associated with adverse birth outcomes (p"/>
  <result pre="OR 0.78, CI 0.255–2.397) [42]. The two human studies where" exact="ZIKV" post="viral loads were described (Terzian et al and Halai"/>
  <result pre="Two NHP studies met inclusion criteria. McCracken et al described" exact="ZIKV" post="viremia and RNAemia in six rhesus macaques previously experimentally"/>
  <result pre="and RNAemia in six rhesus macaques previously experimentally infected with" exact="DENV" post="in addition to 14 rhesus macaques groups who were"/>
  <result pre="determined by seronegativity to DENV, ZIKV, Japanese encephalitis virus (JEV)," exact="West Nile" post="Virus (WNV) and yellow fever virus (YFV)[30]. In the"/>
  <result pre="(WNV) and yellow fever virus (YFV)[30]. In the DENV-exposed group," exact="DENV" post="exposure occurred &amp;gt;420 days prior to experimental Brazil-ZIKV2015 infection."/>
  <result pre="investigators confirmed DENV-experienced NHP sera obtained day 0 before NHP" exact="ZIKV" post="inoculation recapitulated ADE ZIKV infection profiles in vitro in"/>
  <result pre="sera obtained day 0 before NHP ZIKV inoculation recapitulated ADE" exact="ZIKV" post="infection profiles in vitro in FcγR-bearing U937 and K562"/>
  <result pre="in vitro in FcγR-bearing U937 and K562 cell lines. After" exact="ZIKV" post="inoculation, serial sera and plasma were collected for ten"/>
  <result pre="serial sera and plasma were collected for ten days and" exact="ZIKV" post="viremia/RNAemia was measured by RT-qPCR assay. No statistically significant"/>
  <result pre="assay. No statistically significant differences in magnitude or duration of" exact="ZIKV" post="viremia/RNAemia was observed between the DENV-exposed and DENV-naïve groups"/>
  <result pre="groups [30]. This study also quantitatively measured the presence of" exact="ZIKV" post="in urine, cerebrospinal fluid, vaginal swabs and saliva and"/>
  <result pre="association between flavivirus exposure history and RT-qPCR confirmed presence of" exact="ZIKV" post="in these other compartments. Finally, the investigators noted no"/>
  <result pre="clinical endpoints, histopathology, biochemistry or hematological indices measured in the" exact="DENV" post="naïve and DENV exposed groups, although they acknowledged that"/>
  <result pre="biochemistry or hematological indices measured in the DENV naïve and" exact="DENV" post="exposed groups, although they acknowledged that a NHP model"/>
  <result pre="that a NHP model is a limited proxy for human" exact="ZIKV" post="disease [30]. Pantoja and colleagues compared the ZIKV viral"/>
  <result pre="for human ZIKV disease [30]. Pantoja and colleagues compared the" exact="ZIKV" post="viral kinetics of n = 4 experimentally ZIKV H/PF/2013"/>
  <result pre="compared the ZIKV viral kinetics of n = 4 experimentally" exact="ZIKV" post="H/PF/2013 inoculated rhesus macaques with a history of experimental"/>
  <result pre="This was compared to a group of n = 4" exact="ZIKV" post="rhesus infected macaques with no prior DENV or ZIKV"/>
  <result pre="n = 4 ZIKV rhesus infected macaques with no prior" exact="DENV" post="or ZIKV exposure [43]. Like McCracken et al, they"/>
  <result pre="4 ZIKV rhesus infected macaques with no prior DENV or" exact="ZIKV" post="exposure [43]. Like McCracken et al, they too confirmed"/>
  <result pre="exposure [43]. Like McCracken et al, they too confirmed that" exact="DENV" post="immune sera elicited ADE of a ZIKV strain in-vitro."/>
  <result pre="too confirmed that DENV immune sera elicited ADE of a" exact="ZIKV" post="strain in-vitro. Sera specimens were collected on days 1–10,"/>
  <result pre="specimens were collected on days 1–10, 15, and 30 after" exact="ZIKV" post="inoculation and ZIKV viremia was measured by qRT-PCR. While"/>
  <result pre="on days 1–10, 15, and 30 after ZIKV inoculation and" exact="ZIKV" post="viremia was measured by qRT-PCR. While they observed a"/>
  <result pre="measured by qRT-PCR. While they observed a shorter duration of" exact="ZIKV" post="viremia in DENV-exposed NHP (25 vs 31 viremia days),"/>
  <result pre="DENV-experienced and DENV-naive groups, nor was there correlation between peak" exact="ZIKV" post="titer and day minus-30 (pre-challenge) DENV sero-titers [43]. No"/>
  <result pre="there correlation between peak ZIKV titer and day minus-30 (pre-challenge)" exact="DENV" post="sero-titers [43]. No difference in urine and saliva ZIKV"/>
  <result pre="(pre-challenge) DENV sero-titers [43]. No difference in urine and saliva" exact="ZIKV" post="PCR positivity was noted between the DENV exposed and"/>
  <result pre="urine and saliva ZIKV PCR positivity was noted between the" exact="DENV" post="exposed and DENV naïve groups. While a detailed comparison"/>
  <result pre="ZIKV PCR positivity was noted between the DENV exposed and" exact="DENV" post="naïve groups. While a detailed comparison of cytokine levels"/>
  <result pre="cytokine levels between the two groups did suggest that prior" exact="DENV" post="exposure modulated ZIKV cytokine profiles, this conclusion was subject"/>
  <result pre="the two groups did suggest that prior DENV exposure modulated" exact="ZIKV" post="cytokine profiles, this conclusion was subject to both small"/>
  <result pre="a consideration in comparing biochemistry, hematological and clinical markers of" exact="ZIKV" post="infection between the DENV exposed and DENV naïve cohorts."/>
  <result pre="biochemistry, hematological and clinical markers of ZIKV infection between the" exact="DENV" post="exposed and DENV naïve cohorts. There were only minor"/>
  <result pre="clinical markers of ZIKV infection between the DENV exposed and" exact="DENV" post="naïve cohorts. There were only minor differences in these"/>
  <result pre="statistically significant drop in neutrophil count at day 7 post" exact="ZIKV" post="inoculation in the DENV exposed group, (ii) a statistically"/>
  <result pre="neutrophil count at day 7 post ZIKV inoculation in the" exact="DENV" post="exposed group, (ii) a statistically significant increase in the"/>
  <result pre="increase in the percent monocyte distribution at day 7 post" exact="ZIKV" post="inoculation in the DENV exposed group, and (iii) a"/>
  <result pre="monocyte distribution at day 7 post ZIKV inoculation in the" exact="DENV" post="exposed group, and (iii) a non-statistically significant trend toward"/>
  <result pre="non-statistically significant trend toward higher ALT values one week after" exact="ZIKV" post="inoculation in the DENV naïve group. Non-human primate study"/>
  <result pre="higher ALT values one week after ZIKV inoculation in the" exact="DENV" post="naïve group. Non-human primate study pooled-analysis The NHP study"/>
  <result pre="same way in ZIKV-inoculated rhesus macaques with and without known" exact="DENV" post="exposure. As either study may have been underpowered to"/>
  <result pre="study may have been underpowered to detect small increases in" exact="ZIKV" post="viremia due to prior DENV exposure, we undertook a"/>
  <result pre="to detect small increases in ZIKV viremia due to prior" exact="DENV" post="exposure, we undertook a pooled-analysis to increase the effective"/>
  <result pre="published data points from Pantoja et al (n = 4" exact="DENV" post="naïve NHP, n = 2 DENV-1 exposed NHP and"/>
  <result pre="NHPs in this pooled dataset had a mean and median" exact="ZIKV" post="peak RNAemia of 6.61 and 6.80 log10 genome equivalents/mL"/>
  <result pre="skewness of the data after log transformation. The mean peak" exact="ZIKV" post="RNAemia was higher in the DENV-exposed group (6.86 log10"/>
  <result pre="t-test, p = 0.22 two sided t-test). The median peak" exact="ZIKV" post="RNAemia was also higher in the DENV-exposed group (6.88"/>
  <result pre="The caveats to interpreting this pooled result include differences in" exact="ZIKV" post="strains used, reproducibility of RNAemia/viremia measurements between the two"/>
  <result pre="between the two studies and differences in time intervals between" exact="DENV" post="and ZIKV exposure. Nevertheless, these results would be consistent"/>
  <result pre="two studies and differences in time intervals between DENV and" exact="ZIKV" post="exposure. Nevertheless, these results would be consistent with the"/>
  <result pre="seen in the eligible human studies that an increase in" exact="ZIKV" post="viremia in those with prior DENV exposure is possible,"/>
  <result pre="that an increase in ZIKV viremia in those with prior" exact="DENV" post="exposure is possible, but of a magnitude unlikely to"/>
  <result pre="eligible human studies we have identified data suggesting that prior" exact="DENV" post="infection may lead to greater ZIKV viremia compared to"/>
  <result pre="data suggesting that prior DENV infection may lead to greater" exact="ZIKV" post="viremia compared to those without prior DENV infection in"/>
  <result pre="lead to greater ZIKV viremia compared to those without prior" exact="DENV" post="infection in both humans and NHPs [41, 42]. However,"/>
  <result pre="GBS or a composite &quot;clinical severity score�? in those with" exact="ZIKV" post="infections who had previously been infected with DENV, when"/>
  <result pre="previously been infected with DENV, when compared to those acute" exact="ZIKV" post="infections with no prior DENV infection [5, 41, 42]."/>
  <result pre="when compared to those acute ZIKV infections with no prior" exact="DENV" post="infection [5, 41, 42]. In addition, Terzian et al"/>
  <result pre="in inflammatory cytokines associated with the trend toward higher median" exact="ZIKV" post="viral loads in DENV IgG+ individuals [41]. Taken together,"/>
  <result pre="with the trend toward higher median ZIKV viral loads in" exact="DENV" post="IgG+ individuals [41]. Taken together, the current evidence from"/>
  <result pre="current evidence from human and NHP studies suggests that prior" exact="DENV" post="infection may cause a small rise in subsequent ZIKV"/>
  <result pre="prior DENV infection may cause a small rise in subsequent" exact="ZIKV" post="viremia but that this is likely not clinically relevant."/>
  <result pre="and secondary infections [28]. It may be that enhancement of" exact="ZIKV" post="replication would be more likely to occur several years"/>
  <result pre="to occur several years post-DENV exposure as cross-neutralizing titers of" exact="DENV" post="wane over time [28]. The human studies identified in"/>
  <result pre="systematic review did not ascribe a time dimension to prior" exact="DENV" post="exposure and therefore may have missed an effect that"/>
  <result pre="time-dependent. This could be explicitly examined should further outbreaks of" exact="ZIKV" post="occur in the Americas or in other regions with"/>
  <result pre="occur in the Americas or in other regions with syndemic" exact="DENV" post="circulation that may be at risk of major ZIKV"/>
  <result pre="syndemic DENV circulation that may be at risk of major" exact="ZIKV" post="epidemics [14]. The choice of serological assay used in"/>
  <result pre="most of the human studies examining the role of prior" exact="DENV" post="exposure on ZIKV outcomes was the major limitation in"/>
  <result pre="human studies examining the role of prior DENV exposure on" exact="ZIKV" post="outcomes was the major limitation in interpreting these data."/>
  <result pre="study. For this reason, it is difficult to infer that" exact="DENV" post="and not some other related flavivirus infection and/or flavivirus"/>
  <result pre="and/or flavivirus vaccine product was the cause of the positive" exact="DENV" post="IgG results. This could cause misclassification bias of the"/>
  <result pre="The paucity of eligible studies is remarkable given that the" exact="ZIKV" post="pandemic caused over 583,000 suspected and 223,000 confirmed ZIKV"/>
  <result pre="the ZIKV pandemic caused over 583,000 suspected and 223,000 confirmed" exact="ZIKV" post="autochthonous cases across 49 countries and territories in the"/>
  <result pre="Our systematic review also prompts further study into whether prior" exact="ZIKV" post="exposure may worsen DENV clinical outcomes. The global ZIKV"/>
  <result pre="prompts further study into whether prior ZIKV exposure may worsen" exact="DENV" post="clinical outcomes. The global ZIKV outbreak has resulted in"/>
  <result pre="prior ZIKV exposure may worsen DENV clinical outcomes. The global" exact="ZIKV" post="outbreak has resulted in a large population primed with"/>
  <result pre="ZIKV outbreak has resulted in a large population primed with" exact="ZIKV" post="within DENV endemic areas and it is unclear how"/>
  <result pre="has resulted in a large population primed with ZIKV within" exact="DENV" post="endemic areas and it is unclear how ZIKV exposure"/>
  <result pre="ZIKV within DENV endemic areas and it is unclear how" exact="ZIKV" post="exposure on a population level will shape future DENV"/>
  <result pre="how ZIKV exposure on a population level will shape future" exact="DENV" post="epidemics and clinical DENV outcomes in this region, a"/>
  <result pre="a population level will shape future DENV epidemics and clinical" exact="DENV" post="outcomes in this region, a reverse of the study"/>
  <result pre="in this work. While existing data so far suggests that" exact="ZIKV" post="circulation in the Americas was associated with a contemporaneous"/>
  <result pre="in the Americas was associated with a contemporaneous reduction in" exact="DENV" post="cases [47], it remains to be seen whether waning"/>
  <result pre="DENV cases [47], it remains to be seen whether waning" exact="ZIKV" post="antibodies over time may subsequently cause DENV infections with"/>
  <result pre="seen whether waning ZIKV antibodies over time may subsequently cause" exact="DENV" post="infections with higher viral loads and therefore trigger particularly"/>
  <result pre="infections with higher viral loads and therefore trigger particularly large" exact="DENV" post="epidemics, a phenomenon seen when DENV serotypes sequentially circulate"/>
  <result pre="therefore trigger particularly large DENV epidemics, a phenomenon seen when" exact="DENV" post="serotypes sequentially circulate through a geographic region [48]. Indeed,"/>
  <result pre="through a geographic region [48]. Indeed, data exists suggesting that" exact="ZIKV" post="itself may promote ADE during a subsequent DENV infection,"/>
  <result pre="suggesting that ZIKV itself may promote ADE during a subsequent" exact="DENV" post="infection, with a study of NHP observing higher peak"/>
  <result pre="a study of NHP observing higher peak DENV-2 viremia in" exact="ZIKV" post="exposed rhesus macaques [9]. Further studies, ideally leveraging prospective"/>
  <result pre="data file. References References 1PlourdeAR, BlochEM. A Literature Review of" exact="Zika" post="Virus. Emerging infectious diseases. 2016;22(7):1185–92. 10.3201/eid2207.15199027070380 2FagbamiAH. Zika virus"/>
  <result pre="Review of Zika Virus. Emerging infectious diseases. 2016;22(7):1185–92. 10.3201/eid2207.15199027070380 2FagbamiAH." exact="Zika" post="virus infections in Nigeria: virological and seroepidemiological investigations in"/>
  <result pre="MonsS, LastereS, RocheC, VanhomwegenJ, et al.Guillain-Barre Syndrome outbreak associated with" exact="Zika" post="virus infection in French Polynesia: a case-control study. Lancet"/>
  <result pre="6FergusonNM, CucunubaZM, DorigattiI, Nedjati-GilaniGL, DonnellyCA, BasanezMG, et al.EPIDEMIOLOGY. Countering the" exact="Zika" post="epidemic in Latin America. Science (New York, NY). 2016;353(6297):353–4."/>
  <result pre="7Schuler-FacciniL, RibeiroEM, FeitosaIM, HorovitzDD, CavalcantiDP, PessoaA, et al.Possible Association Between" exact="Zika" post="Virus Infection and Microcephaly—Brazil, 2015. MMWR Morbidity and mortality"/>
  <result pre="VenturaCV, FonsecaEB, et al.Characterizing the Pattern of Anomalies in Congenital" exact="Zika" post="Syndrome for Pediatric Clinicians. JAMA pediatrics. 2017;171(3):288–95. 10.1001/jamapediatrics.2016.398227812690 9AliotaMT,"/>
  <result pre="Virus Network. Antiviral Res. 2017;144:223–46. 10.1016/j.antiviral.2017.06.00128595824 10PetersenLR, JamiesonDJ, PowersAM, HoneinMA." exact="Zika" post="Virus. The New England journal of medicine. 2016;374(16):1552–63. 10.1056/NEJMra160211327028561"/>
  <result pre="of medicine. 2016;374(16):1552–63. 10.1056/NEJMra160211327028561 11PosenHJ, KeystoneJS, GubbayJB, MorrisSK. Epidemiology of" exact="Zika" post="virus, 1947–2007. BMJ global health. 2016;1(2):e00008710.1136/bmjgh-2016-00008728588942 12FoyBD, KobylinskiKC, Chilson"/>
  <result pre="BlitvichBJ, Travassos da RosaA, HaddowAD, et al.Probable non-vector-borne transmission of" exact="Zika" post="virus, Colorado, USA. Emerging infectious diseases. 2011;17(5):880–2. 10.3201/eid1705.10193921529401 13https://www.paho.org/hq/index.php?option=com_content&amp;amp;view=article&amp;amp;id=12390&amp;amp;Itemid=42090&amp;amp;lang=en"/>
  <result pre="25 2018. 14SirajAS, PerkinsTA. Assessing the population at risk of" exact="Zika" post="virus in Asia—is the emergency really over?2017;2(3):e00030910.1136/bmjgh-2017-00030929082009 15Outbreak of"/>
  <result pre="Zika virus in Asia—is the emergency really over?2017;2(3):e00030910.1136/bmjgh-2017-00030929082009 15Outbreak of" exact="Zika" post="virus infection in Singapore: an epidemiological, entomological, virological, and"/>
  <result pre="10.1016/S1473-3099(17)30249-928527892 16PetterssonJH, BohlinJ. Re-visiting the evolution, dispersal and epidemiology of" exact="Zika" post="virus in Asia. 2018;7(1):7910.1038/s41426-018-0082-529739925 17LesslerJ, ChaissonLH, KucirkaLM, BiQ, GrantzK,"/>
  <result pre="KucirkaLM, BiQ, GrantzK, SaljeH, et al.Assessing the global threat from" exact="Zika" post="virus. Science (New York, NY). 2016;353(6300):aaf8160. 18KraemerMU, SinkaME, DudaKA,"/>
  <result pre="de CarvalhoOV, de MendoncaLR, et al.Dengue Virus-Specific Antibodies Enhance Brazilian" exact="Zika" post="Virus Infection. The Journal of infectious diseases. 2017;215(5):781–5. 10.1093/infdis/jiw63828039355"/>
  <result pre="Nature. 2016;536(7614):48–53. 10.1038/nature1893827338953 22PriyamvadaL, HudsonW, AhmedR, WrammertJ. Humoral cross-reactivity between" exact="Zika" post="and dengue viruses: implications for protection and pathology. Emerging"/>
  <result pre="antibody responses after dengue virus infection are highly cross-reactive to" exact="Zika" post="virus. Proceedings of the National Academy of Sciences of"/>
  <result pre="10.1038/ni.351527339099 25BardinaSV, BunducP, TripathiS, DuehrJ, FrereJJ, BrownJA, et al.Enhancement of" exact="Zika" post="virus pathogenesis by preexisting antiflavivirus immunity. Science (New York,"/>
  <result pre="et al.Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from" exact="Dengue" post="Patients Are Protective against Zika Virus. mBio. 2016;7(4). 27DurbinAP."/>
  <result pre="Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against" exact="Zika" post="Virus. mBio. 2016;7(4). 27DurbinAP. Dengue Antibody and Zika: Friend"/>
  <result pre="Dengue Patients Are Protective against Zika Virus. mBio. 2016;7(4). 27DurbinAP." exact="Dengue" post="Antibody and Zika: Friend or Foe?Trends in immunology. 2016;37(10):635–6."/>
  <result pre="Friend or Foe?Trends in immunology. 2016;37(10):635–6. 10.1016/j.it.2016.08.00627599407 28MahalingamS, TeixeiraMM, HalsteadSB." exact="Zika" post="enhancement: a reality check. The Lancet Infectious diseases. 2017;17(7):686–8."/>
  <result pre="De La BarreraR, et al.Impact of prior flavivirus immunity on" exact="Zika" post="virus infection in rhesus macaques. PLoS Pathog. 2017;13(8):e100648710.1371/journal.ppat.100648728771605 31http://prisma-statement.org/,"/>
  <result pre="HarrisE. Recent advances in understanding the adaptive immune response to" exact="Zika" post="virus and the effect of previous flavivirus exposure. EMBO"/>
  <result pre="2018;19(2):206–24. 10.15252/embr.20174530229282215 35RothanHA, BidokhtiMRM, ByrareddySN. Current concerns and perspectives on" exact="Zika" post="virus co-infection with arboviruses and HIV. Journal of autoimmunity."/>
  <result pre="A Tale of Two Viruses: Does Heterologous Flavivirus Immunity Enhance" exact="Zika" post="Disease?Trends in microbiology. 2018;26(3):186–90. 10.1016/j.tim.2017.10.00429122447 37https://academic.oup.com/ofid/issue/4/suppl_1 accessed July 25"/>
  <result pre="Cytokine Response Profile Does Not Support Antibody-Dependent Enhancement in Dengue-Primed" exact="Zika" post="Virus-Infected Patients. Clinical infectious diseases: an official publication of"/>
  <result pre="Nielsen-SainesK, MoreiraML, de SequeiraPC, JuniorJPP, de Araujo ZinA, et al.Maternal" exact="Zika" post="Virus Disease Severity, Virus Load, Prior Dengue Antibodies, and"/>
  <result pre="ZinA, et al.Maternal Zika Virus Disease Severity, Virus Load, Prior" exact="Dengue" post="Antibodies, and Their Relationship to Birth Outcomes. Clinical infectious"/>
  <result pre="44BalmasedaA, StettlerK, Medialdea-CarreraR, ColladoD, JinX, ZambranaJV, et al.Antibody-based assay discriminates" exact="Zika" post="virus infection from other flaviviruses. 2017;114(31):8384–9. 10.1073/pnas.170498411428716913 45https://consise.tghn.org/about/working-group-projects/, accessed"/>
  <result pre="other flaviviruses. 2017;114(31):8384–9. 10.1073/pnas.170498411428716913 45https://consise.tghn.org/about/working-group-projects/, accessed August 20, 2018 46SaenzC." exact="Zika" post="virus: ethics preparedness for old and new challenges. The"/>
  <result pre="47RibeiroGS, KikutiM, TauroLB, NascimentoLCJ, CardosoCW, CamposGS, et al.Does immunity after" exact="Zika" post="virus infection cross-protect against dengue?The Lancet Global health. 2018;6(2):e140–e1."/>
 </snippets>
</snippetsTree>
